California-based psychedelic biotechnology company Freedom Biosciences has emerged from stealth, raising USD 10.5 million in a seed funding round led by MBX Capital, with participation from PsyMed Ventures, Village Global, and The Yale Startup.
The proceeds from the round will be directed toward advancing its psychedelic therapy programs, including its lead ketamine-based therapy FREE001.
Founded in 2021, Freedom Biosciences develops psychedelic-based combination therapeutics for mental health disorders such as major depressive disorder (MDD). The company’s drug discovery platform leverages the already-known pharmacology of ketamine and other psychedelics to identify new therapies that are expected to be more effective than existing ketamine and psychedelic therapies that are administered alone.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.